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Should routine serological screening for HCV be mandatory in 
HIV/AIDS patients enrolling for HAART in South Africa?
Maemu P Gededzha, M Jeffrey Mphahlele, Azwidowi Lukhwareni, Selokela G Selabe
To the Editor: Globally, an estimated 170 million people (about 3% 
of the world’s population) have been infected with hepatitis C virus 
(HCV). HCV, a member of the Hepacivirus genus in the Flaviviridae 
family, possesses a single stranded, positive-sense RNA genome of 
approximately 9.6 kilobase (kb), and is the major cause of chronic 
hepatitis, cirrhosis and hepatocellular carcinoma.1 In Africa, HCV 
prevalence ranges from <3% in South Africa to >20% in Egypt. In 
South Africa, there is a low prevalence from 0.16% to 1.8%,2-5 but this 
is higher in high-risk individuals, e.g. 39.4% in haemophiliacs and 
4.8% in chronic dialysis patients.2
Some 4 - 5 million people globally are co-infected with HCV and 
human immunodeficiency virus (HIV).6 Co-infection with HCV 
and HIV is common owing to shared routes of transmission – via 
blood and blood products and sharing of needles for injecting drugs.7 
The introduction of highly active antiretroviral therapy (HAART) 
dramatically improved the management of HIV patients. However, 
co-infections with opportunistic infections such as HCV and hepatitis 
B virus (HBV) remain a major problem. Patients with HIV/HCV 
co-infection have less immune reconstitution than patients with 
HIV infection alone,8 and HAART may worsen the outcome of HCV 
disease, through enhancement of drug-induced hepatotoxicity.9
South Africa has scaled up HAART for treatment of HIV/AIDS 
in the public health sector since April 2003. However, research 
programmes to monitor the efficacy of HAART in HIV/AIDS 
patients co-infected with HBV and HCV do not exist. We have shown 
that 63% of HIV-positive South African patients initiating HAART 
have past or present HBV infection.10 However, few data exist on the 
burden of HCV prevalence in HIV patients. One study demonstrated 
a low prevalence of 1.9%,11 and another a high prevalence of 13.4% 
in KwaZulu-Natal.12
Methods
We investigated the burden of HCV co-infection in HIV-positive 
patients enrolling for HAART at a tertiary hospital in Pretoria. The 
study population comprised 653 serum samples stored at -70oC 
from adult HIV/AIDS patients who were candidates for HAART at 
Tshepang Clinic, Dr George Mukhari Hospital (DGMH), Pretoria, 
from 2004 to 2006. The Research, Ethics and Publication Committee 
of the University of Limpopo, Medunsa Campus, approved the study. 
All sera were screened for anti-HCV marker using the AxSYM assays 
version 3.0 (Abbott Laboratories, North Chicago) following the 
manufacturer’s instructions.
Owing to limited serum volumes to confirm the initial screening 
results with a second serological assay, all anti-HCV positives 
(samples with S/CO, i.e. ratio of the sample rate (S) to the cut-off 
rate (CO) for each sample and control) above 5.23 and preliminary 
positives (samples with S/CO between 1.00 and 5.00) were subjected 
to in-house qualitative reverse transcription-polymerase chain 
reaction (RT-PCR) assay. Viral RNA was extracted from serum with 
the QIAmp viral mini RNA kits (Qiagen Gmbh, Germany), followed 
by PCR targeting of the highly conserved 5’-untranslated region 
(UTR) as previously described with slight modifications.13 PCR 
positive samples were sequenced to confirm the specificity of the 
PCR products (SpectruMedix SCE 2410 Genetic Analysis System, 
LLC, PA).
Results
Only 1.2% (8/653) of samples were positive for anti-HCV, with S/CO 
values ranging from 5.69 to 37.8. Of these 8 samples, HCV RNA was 
detected in only one, which had the highest anti-HCV titre of 37.8 
(Table I). Sequencing confirmed that the RT-PCR product is HCV-Corresponding author: S Selabe (selokela@yahoo.com)
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specific. In contrast, 20.7% (135/653) of preliminary positive samples 
had S/CO values ranging from 1.02 to 4.48. None of these samples 
tested positive for HCV by RT-PCR.
Discussion
Laboratory diagnosis of HCV has major limitations as most available 
serological assays do not distinguish between acute, chronic and 
past infections. HCV RNA positive is regarded to be a marker of 
replication, whereas HCV RNA negative in anti-HCV positive 
patients indicates either resolved infection or very low viraemia with 
HCV RNA levels below the detection limit of the RT-PCR assay.
South Africa has one of the highest number of people living with 
HIV.14 This study found a sero-prevalence of only 1.2% in HIV/AIDS 
patients enrolling for HAART in Pretoria. All but one appeared 
to have past or resolved HCV infection as indicated by a negative 
RT-PCR assay. Comparable findings were reported in pregnant 
women from Gabon.15 During the natural history of HCV infection, 
20 - 30% of infected individuals eliminate the virus spontaneously.16 
The low prevalence of HCV antibodies in our study could be due to 
missed HCV antibodies, as many HIV/AIDS patients fail to generate 
antibodies owing to immunosuppression,17 and RT-PCR assay was 
used only to confirm anti-HCV positives or preliminary positives. 
The high number of HCV RNA negative results may also be the 
result of false anti-HCV positives with AxSYM 3.0 assay as the initial 
screening results were not confirmed with another serological assay 
owing to insufficient sera. Other limitations include lack of fresh 
samples, insufficient volume and that the study was conducted on 
patients attending a tertiary HIV referral clinic in a hospital setting.
Our study shows that most HIV/AIDS patients initiating HAART 
at DGMH have low exposure to, or active, HCV infection. In contrast 
to high rates of HBV and HIV co-infection in similar patients at 
DGMH, it appears that HIV/AIDS is not a risk factor for increased 
detection of HCV co-infection. While our findings do not support 
mandatory HCV screening in HIV/AIDS patients initiating HAART 
in South Africa, consideration should be given to patients who may 
be at an increased risk, such as HIV-positive haemophiliacs, injection 
drug users and diabetics. HCV antiviral therapy that may benefit such 
high-risk patients is increasingly becoming available in South African 
tertiary public hospitals through public-private partnerships.
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Table I. Summary of patients with reactive anti-HCV
Patient Age Gender
Anti-HCV 
(S/CO)
RT-PCR 
assay
1 37 F 37.08 +
2 51 M 6.29 -
3 30 M 7.77 -
4 30 F 5.69 -
5 43 M 11.62 -
6 36 F 6.42 -
7 33 F 11.48 -
8 37 F 6.05 -
